Physician profile
Thomas A Capozza
NPI 1609848860
$44,252.86
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $44K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $35,737.02 | 2019 | |
| Intercept Pharmaceuticals, INC. | $7,352.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.10 | 2019 | |
| Abbvie INC. | $200.26 | 2019 | |
| Janssen Biotech, INC. | $190.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.27 | 2019 | |
| Pfizer INC. | $80.07 | 2019 | |
| Shionogi INC | $57.26 | 2019 | |
| Shire North American Group INC | $56.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $34.55 | 2019 | |
| Allergan, INC. | $18.19 | 2019 | |
| Qol Medical, LLC | $17.26 | 2019 | |
| Merck Sharp & Dohme LLC | $15.81 | 2019 | |
| Romark Laboratories, Lc | $14.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$41.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Capozza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.